| HOME >> BIOLOGY >> TECHNOLOGY |
About Aviir
Aviir was founded in 2005 by cardiologists and scientists from the Stanford University School of Medicine to focus on discovery, development and commercialization of innovative diagnostic tests. The biotechnology company specializes in developing proprietary diagnostic tests that will assist in identifying patients that are truly at high risk for the development of a cardiac event. Aviir's proprietary MiRisk™ and TruRisk™ assessments objectively identify, by a simple blood draw, individuals who are at a high risk of a cardiac event over the next five years. Aviir's CLIA laboratory (Irvine, CA) complements these novel tests with a wide range of additional tests for risk assessment and therapeutic monitoring of cardiovascular disease and related metabolic disorders – including pharmacogenomics and genetic tests. www.aviir.com
"There is currently a significant yet unmet clinical need in the medical community for more effective ways to identify individuals at high risk of a heart attack who are missed by current evaluation methods. Providing an accurate assessment of the patient's overall heart health is the first step in prevention of cardiovascular disease," stated Douglas Harrington, M.D., Chief Executive Officer of Aviir.
"At Aviir, our ultimate goal is to help physicians identify those patients who are at serious risk of experiencing a heart attack but are completely unaware of their precarious condition. Armed with better information, physicians will be able to customize individualized treatment plans with the goal of improving patient therapeutic compliance, reduce their risk of heart attacks, and decrease the overall cost of care," Dr. Harrington added.
Learn more at www.aviir.com
Learn more at
| SOURCE Aviir Diagnostic Laboratory Copyright©2010 PR Newswire. All rights reserved |